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Abstract
Background: Vertebral osteomyelitis (VO) may lead to disabling neurologic complications. Little evidence exists on
optimal antibiotic management.
Methods: All patients with primary, non-implant VO, admitted from 2000–2010 were retrospectively analyzed.
Patients with endocarditis, immunodeficiency, vertebral implants and surgical site infection following spine surgery
were excluded. Persistence of clinical or laboratory signs of inflammation at 1 year were defined as treatment
failure. Logistic regression was used to estimate the odds ratios (OR) of switch to an oral regimen after 2 weeks.
Results: Median antibiotic treatment was 8.1 weeks in 61 identified patients. Switch to oral antibiotics was
performed in 72% of patients after a median intravenous therapy of 2.7 weeks. Switch to oral therapy was already
performed after two weeks in 34% of the patients. A lower CRP at 2 weeks was the only independent predictor
for switch to oral therapy (OR 0.7, 95% confidence interval 0.5-0.9, p = 0.041, per 10 mg/l increase). Staphylococcus aureus
was the most frequently isolated microorganism (21%). Indications for surgery, other than biopsy, included debridement
with drainage of epidural or paravertebral abscess (26 patients; 42%), and CT - guided drainage (3 patients).
During the follow-up, no recurrences were observed but 2 patients died of other reasons than VO, i.e. the 1 year
intention to treat success rate was 97%.
Conclusions: Cure rates for non-implant VO were very high with partly short intravenous and overall antibiotic therapy.
Switching to an oral antibiotic regimen after two weeks intravenous treatment may be safe, provided that CRP has
decreased and epidural or paravertebral abscesses of significant size have been drained.
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Background
The incidence of vertebral osteomyelitis (VO) is increas-
ing, primarily affecting elderly patients and those with
comorbidities [1,2]. Complications of VO, i.e. epidural,
paravertebral or psoas abscesses, which result from dir-
ect seeding of the microorganism in different compart-
ments [1], may lead to longer hospital stay and higher
mortality. To date, there are no consistent data from ran-
domized controlled trials to guide the optimal duration and
appropriate route of antibiotic therapy. Recommendations
for the length of antibiotic therapy vary considerably [3-5],
with suggestion of parenteral treatment between 3 and
8 weeks [6-9]. The mean treatment duration in a French
multicentre observational prospective study, involving 110
patients, was 14.7 weeks, with minimum length ranging
from 6 to 12 weeks according to the treating centre [6].
Other observational studies show distinctive differences in
recurrence rates for treatment duration of less than
4 weeks (>14%), 6 weeks (10%), 8 weeks (>15%) compared
to longer than 12 weeks (3.9%) [10].
We retrospectively investigated patients with primary
VO in a tertiary care hospital during a 10-year period with
the aim to assess predictors of switching from intravenous
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to an oral antibiotic regimen and to investigate the clinical
outcome dependent on different treatment durations.
Methods
Study population and design
This study is a retrospective analysis of all patients diag-
nosed with VO, seen by an Infectious Disease specialist,
at the University Hospital of Basel, Switzerland, between
2000 and 2010. The University Hospital of Basel is a ter-
tiary 800-bed institution serving the northwestern part
of Switzerland with a population of approximately half a
million people.
Patients were selected from the Infectious Diseases pa-
tient database. Supplementary data collected by chart
review included demographic characteristics, date of
hospitalisation, co-morbidities (diabetes mellitus, cardio-
vascular disease, immunosuppression and renal insuffi-
ciency). Blood tests included creatinine, white blood cell
count and C-reactive protein (CRP). Further data com-
prised the clinical presentation of VO such as back pain,
fever, neurologic deficits at presentation (i.e. limb weak-
ness, dysesthesia or sensory loss, retention of urine and
radiculopathy), the presence of endocarditis, radiological
images, microbiological tests (blood cultures, bone biop-
sies), antibiotic treatment regimen including route of
administration (oral or intravenous) and duration and
surgical procedures.
Diagnosis of VO was made if two of the following cri-
teria were present: (1) clinical presentation compatible
with VO [1] such as fever, back pain or neurological defi-
cits, (2) compatible radiological images [11,12] and (3)
identification [13] of pathogen by blood culture, needle
biopsy or surgical biopsy. We excluded patients with
endocarditis, as the recommended intravenous treat-
ment is at least 4 weeks, surgical site infection following
spine surgery because a 2-week intravenous antibiotic
course after extensive debridement is generally consid-
ered to be adequate before switching to an oral regimen
[14,15] and spinal implants or tuberculous VO because
of the longer treatment duration [16,17].
Outcome measures
The physicians, caring for patients after discharge from
hospital, were requested to provide follow-up data on
the clinical course, laboratory parameters and treatment
at 4 and 6 weeks and 1 year after diagnosis of VO.
Recovery was defined as disappearance of all clinical
signs and symptoms of VO with no residual disability [18].
Treatment failure was defined as the persistence of
clinical signs and symptoms of VO, i.e. fever, residual
pain or neurological symptoms, or laboratory signs of
inflammation with no other explanation, VO-related
re-hospitalization, relapse or VO-related death. The out-
come was evaluated after completing the prescribed
antibiotic therapy and at 1 year by in-hospital data and a
questionnaire sent to the treating physicians.
Statistical analysis
Basic demographic characteristics, co-morbidities, labora-
tory and microbiological parameters, surgical and antibiotic
management were compared using the X
2 test or Fisher’s
exact test for categorical variables and the Mann–Whitney
test for continuous variables. Logistic regression was used
to estimate the odds ratios (OR) of switch to an oral regi-
men after 2 weeks.
All analyses were performed using STATA™ software
version 11 for Windows (StataCorp, College Station, TX,
USA). This study was approved by the local Ethics Com-
mittee (Ethische Komission beider Basel).
Results
Study population
Among 129 patients with VO, 68 patients were excluded
because of spinal implants (25), endocarditis (19), surgical
site infections (10) and missing follow-up data (14). The
final analysis was performed on 61 patients. The median
age was 65 years [interquartile range (IQR) 51–76] and
most patients were male (61%). Baseline characteristics
are shown in Table 1.
Clinical presentation and diagnosis of VO
Twenty-seven patients had no comorbidities, all other
patients were reported to have more than 1 underlying
medical disease, arterial hypertension being the most
frequent (39%) followed by coronary heart disease (25%),
diabetes mellitus (11%) and renal impairment, i.e. cre-
atinine clearance <80 ml/min (8%). Back pain was by far
the most common presenting symptom (93%), followed
by fever (28%). Neurologic deficits at presentation were
reported in 16% and abscess formation (i.e. epidural or
paravertebral) was found in 51% of patients.
Staphylococcus aureus and coagulase-negative staphylo-
cocci were the most frequently isolated microorganisms,
i.e. 21% and 17% respectively, followed by gram-negative
bacteria (28%), streptococci (20%) and Propionibacter-
ium acnes (5%). In 8 patients no causing microorganism
could be identified.
Diagnostic tools for bacteriologic diagnosis included
blood cultures, computerized tomography (CT) - guided
needle biopsy and open biopsy. In 49 patients blood cul-
tures were performed. Of these, 25 (51%) were positive
with microorganisms regarded as causative pathogens
for the VO. Biopsies (CT-guided and open) were per-
formed in 50 patients (82%) yielding a causative bacter-
ium in 92%.
Radiological techniques for the diagnosis of VO in-
cluded computerized tomography (CT) with contrast
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medium in 10 patients (16%) and/or magnetic resonance
tomography (MRI) in 58 patients (95%).
Management of vertebral osteomyelitis
All patients received empirical antibiotic treatment for
VO according to internal guidelines, after diagnostic
procedures have been performed being amoxicillin-
clavulanate and ceftriaxone the most frequently used
(Table 2). The empiric antibiotic therapy was retrospect-
ively considered to be adequate in 47 patients (83%) ac-
cording to definite microbiological results. The median
duration of antibiotic treatment was 57 days (8.1 weeks;
IQR 44–83 days). Switch to an oral antibiotic regimen
was performed in 72% of patients after a median intra-
venous therapy of 19 days (2.7 weeks; IQR 14–27 days).
In 21 patients (34%) the switch to oral therapy was per-
formed after 2 weeks of intravenous treatment. The
most frequently used oral antibiotic treatment was cip-
rofloxacin or another quinolone alone (35%) and a com-
bination of ciprofloxacin and rifampin (26%).
Indications for surgery, other than biopsy, included
debridement with drainage of the abscess in 26 of 31
patients with epidural or paravertebral abscess, whereas
CT - guided drainage of the abscess was performed in 3
patients. In 2 patients no drainage or surgery was per-
formed due to the very small size of epidural abscess.
Predictors of switch to an oral antibiotic regimen after
2 weeks
A univariate and multivariate analysis was performed.
After adjustment for age, gender, comorbidity, fever and
neurological deficits at diagnosis, microorganisms, ab-
scesses (i.e. epidural or paravertebral), surgery and labora-
tory parameters, correct empirical antibiotic therapy, as
well as antibiotic regimen containing rifampicin, lower
CRP at 2 weeks compared to baseline CRP was the only
independent predictor of switching to an oral antibiotic
regimen after 2 weeks (OR 0.7, 95% CI 0.5-0.9, p = 0.041,
per 10 mg/l increase).
Outcome
A complete follow-up was available for 61 patients. Dur-
ing the follow-up, 2 patients died of metastasizing colo-
rectal and bronchial carcinoma, 47 and 51 days after
diagnosis of VO, i.e. the 1-year success rate in an
intention to treat analysis was 97% and there were no
reported re-hospitalisations and/or treatment failures
because of VO.





Median age, IQR 65 51–76
Median BMI, IQR 25 21–28
Arterial hypertension 24 39
Diabetes mellitus 7 11
Coronary heart disease 15 25
Renal impairment (clearance <80 ml/min.) 5 8
Fever (>38°C) 17 28
Back pain 57 93
Neurologic al deficits 10 16
Epidural abscess 31 51
Median leucocytes count, IQR (109/l) 10.1 8.0–12.5
Median C-reactive protein (mg/l) 100 62–186
Microorganism Staphylococcus aureus 11 21
Coagulase negative staphylococci 9 17
Streptococci spp. 12 20
Escherichia coli 6 11
Klebsiella spp. 2 4
Pseudomonas aeruginosa 7 13
Propionibacterium acnes 3 6
Other or unknown 11 21
*unless otherwise stated.
Table 2 Antibiotic treatment and surgical management of
61 patients with primary spondylodiscitis
Characteristic All patients
n* %*
Procedure Surgery 26 43
CT-guided drainage 3 5
Adequate empirical antibiotic therapy 47 83




Other beta-lactame antibiotics 5 8
Ciprofloxacin 5 8
Other 2 3
Switch to oral antibiotic treatment 43 72
Oral regimen Ciprofloxacin or other chinolone alone 15 35
Ciprofloxacin and clindamycin 5 12
Ciprofloxacin and rifampicin 11 26
Clindamycin alone 3 7
Other 9 21
Antibiotic regimen containing rifampicin 15 25
Median duration of total antibiotic therapy, IQR (days) 57 44–83
*unless otherwise stated.
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Discussion
Our study, involving 61 immunocompentent patients
with primary vertebral osteomyelitis, illustrates that
switching to an oral antibiotic regimen after 2 weeks of
intravenous therapy may be safe, provided that symp-
toms have improved, epidural or paravertebral abscess
has been drained and C-reactive protein levels have
decreased. Importantly, our results do not extend to
patients with endocarditis, surgical site infection and
vertebral implants.
The duration of intravenous therapy has not been
established so far. Several studies described successful
switch to oral antibiotics after 10 days, using oral agents
with a high bio-availability and tissue penetration, i.e.
fluorquinolones, rifampin, fusidic acid and clindamycin
[19], after endocarditis had been excluded [2,20]. In the
study of Beronius et al. [20], however, the median dur-
ation of oral antibiotic therapy after a short parenteral
therapy was 179 days (range 46–640 days), which is
much longer than the therapy duration in our patient col-
lective. This might be due to the fact that 27% of the pa-
tients in the above mentioned study had tuberculous VO.
Thirty-five percent of our patients were treated with
fluorquinolones alone and 26% with a combination of a
fluorquinolone and rifampin, all with good outcome, i.e.
cure. Fluorquinolones are bactericidal drugs and thereby
allow an early switch to the oral route. In a randomized
clinical study, the combination of an oral fluorquinolone
and rifampin in case of staphylococcal bone or joint in-
fections, resulted in cure rates that were similar to those
with the standard intravenous therapy [21].
In our study, a lower CRP at 2 weeks was the only in-
dependent predictor of switching to an oral antibiotic
regimen. Serum CRP level is closely related with the
clinical response to therapy and is therefore the pre-
ferred marker of the course of infection [22]. Criteria for
discontinuation of antimicrobial therapy include reso-
lution of clinical symptoms as well as normalization of
CRP [6,18]. It has been proposed that a weekly decrease
in CRP by 50% represents treatment response [23]. Lack
of improvement in symptoms such as continued fever
and no reduction in pain or a persistently elevated CRP
above 30 mg/l are predictors of treatment failure [22,24].
In our study, the early switch to oral antibiotic therapy,
i.e. after two weeks, if above mentioned criteria are met,
does not seem to be associated with adverse outcome.
In the present study 51% of the patients were found to
have epidural and/or paravertebral abscess formation.
This high number can be explained by the fact that MRI
and/or CT scans were systematically performed in all
patients to establish the diagnosis of VO. All, but two
of the patients (93%) with abscesses required surgery.
This rate is much higher than reported in other studies
[3,25]. All patients with abscess formation were treated
according to our internal guidelines which are in line
with published procedures [1]. This implies surgical
drainage and/or debridement and is likely to have con-
tributed to the high number of surgical intervention in
case of abscess formation.
Open surgical decompression combined with intraven-
ous antibiotic treatment has long been considered the
cornerstone of management for spinal epidural abscess
[26]. Following this management may be associated with
a shorter duration of intravenous therapy in our study.
The aetiological microorganism could be isolated with
blood cultures in 51% and with CT-guided or open biopsy
in 75% of patients. Staphylococcus aureus and gram nega-
tive microorganisms were the most common causative
microorganisms in our patient group. This is in line
with previous studies where Staphylococcus aureus was
the most common isolated organism followed by gram-
negative bacilli, E.coli being the predominant agent
[1,13,27]. Despite exclusion of endocarditis and spinal
implants, as well as surgical site infections, 17% of the mi-
croorganisms detected were coagulase - negative staphylo-
cocci (CoNS) proven by bone biopsies. In these patients,
biopsies were taken before empiric antibiotic therapy was
initiated and CoNS-targeted antibiotic therapy led to reso-
lution of symptoms. CoNS are common pathogens in cases
of sternal osteomyelitis following median sternotomy [28]
and are associated with intra-cardiac device related bacter-
aemia [29,30]. In contrast, they rarely cause osteomyelitis
in the absence of bone devices or in patients without pro-
found immunosuppression [31]. Our findings however
indicate that CoNS might be more often found as the
causative organisms in VO even without foreign bodies or
endocarditis. We speculate that sclerosis of the bone in
ageing patients may predispose to infections with CoNS.
In our study we had excellent outcome results. This
might be due to the reason, that patients with endocar-
ditis, immunodeficiency, vertebral implants and surgical
site infection following spine surgery had been excluded.
Latter mentioned patients tend to have more complica-
tions. E.g. recurrent bacteraemia in case of endocarditis
was independently associated with relapse [18]. Another
reason for the excellent outcome might be the high rate
of drainage in case of abscesses. In the above mentioned
study of Mc Henry et al. [18] surgical treatment resulted
in recovery or improvement in 79% of patients.
A third reason for the excellent outcome is likely the
fact that in every case an infectious disease specialist
was involved and antibiotic therapy had continuously
been adapted. In this respect the very low prevalence of
MRSA may have helped the excellent outcome.
Limitations and strengths
Our results may have a limited generalizability as the
study was performed in a single centre. However, the
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study was conducted over an extended period of time
with consistent results. Limited generalizability is also
given due to the local epidemiology with a very low
prevalence of methicillin-resistant S. aureus (MRSA) of
5-7% (data not shown). Due to frequently co-occuring
resistance to rifampin in MRSA, one of the most import-
ant oral treatment options is futile in many instances. In
our institution, we were able to switch to oral antibiotics
in a large part of patients. A second limitation of the
study is its retrospective study design; we cannot exclude
a selection bias of patients who received a shorter intra-
venous antibiotic treatment. Selection bias may have
occurred because physicians tend to switch earlier to
an oral regimen if the patient has improved, so that
switched patients may be those with better prognosis
and/or more limited disease. On the other hand physi-
cians may have had prolonged the intravenous therapy
in patients which were not responding optimally to the
therapy. Finally, the patient number did not allow for
strong multivariate analyses, e.g. we could not define the
level of C-reactive protein, above which intravenous
therapy should be prolonged.
Our study has also strengths: First, the study covers a
long time period with consistent results. Noteworthy, to
the best of our knowledge, this is the first retrospective
study of a homogenous patient collective (i.e. with pri-
mary vertebral osteomyelitis) after exclusion of patients
with endocarditis, immunodeficiency, spinal implants and
surgical site infection following spine surgery. Further-
more, the patient population was worked up in a meticu-
lous way demonstrated by high rates of microbiological
diagnoses and high rates of diagnosed abscesses.
Conclusion
Our results suggest that switching to an oral antibiotic
regimen after two weeks of intravenous therapy is safe in
immunocompetent patients for primary non-implant ver-
tebral osteomyelitis if epidural or paravertebral abscesses
have been drained and if an oral antibiotic therapy with
documented susceptibility, high bio-availability and bac-
tericidal activity is available. Our results should be con-
firmed by a prospective randomized controlled trial.
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